NO981503L - Anvendelsen av 2-amino-4-(4-fluorbenzylamino)-1-etoksy-karbonylaminobenzen for profylakse og behandling av f÷lgene av akutt og kronisk cerebral redusert gjennombl÷dning samt neurodegenerative sykdommer - Google Patents

Anvendelsen av 2-amino-4-(4-fluorbenzylamino)-1-etoksy-karbonylaminobenzen for profylakse og behandling av f÷lgene av akutt og kronisk cerebral redusert gjennombl÷dning samt neurodegenerative sykdommer

Info

Publication number
NO981503L
NO981503L NO981503A NO981503A NO981503L NO 981503 L NO981503 L NO 981503L NO 981503 A NO981503 A NO 981503A NO 981503 A NO981503 A NO 981503A NO 981503 L NO981503 L NO 981503L
Authority
NO
Norway
Prior art keywords
ethoxycarbonylaminobenzene
fluorobenzylamino
prophylaxis
consequences
acute
Prior art date
Application number
NO981503A
Other languages
English (en)
Other versions
NO316493B1 (no
NO981503D0 (no
Inventor
Angelika Rostock
Christine Tober
Chris Rundfeldt
Reni Bartsch
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of NO981503L publication Critical patent/NO981503L/no
Publication of NO981503D0 publication Critical patent/NO981503D0/no
Publication of NO316493B1 publication Critical patent/NO316493B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO981503A 1995-10-26 1998-04-02 Anvendelsen av 2-amino-4-(4-fluorbenzylamino)-1-etoksy-karbonylaminobenzen for profylakse og behandling av følgene av akutt og kronisk cerebral redusert gjennomblødning samt neurodegenerative sykdommer NO316493B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19539861A DE19539861A1 (de) 1995-10-26 1995-10-26 Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
PCT/DE1996/001951 WO1997015300A2 (de) 1995-10-26 1996-10-15 Verwendung von 4-amino-4-(4-fluorbenzylamino)-1-ethoxycarbonylaminobenzen zur prophylaxe und behandlung der folgen der akuten und chronischen zerebralen minderdurchblutung sowie neurodegenerativer erkrankungen

Publications (3)

Publication Number Publication Date
NO981503L true NO981503L (no) 1998-04-02
NO981503D0 NO981503D0 (no) 1998-04-02
NO316493B1 NO316493B1 (no) 2004-02-02

Family

ID=7775835

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981503A NO316493B1 (no) 1995-10-26 1998-04-02 Anvendelsen av 2-amino-4-(4-fluorbenzylamino)-1-etoksy-karbonylaminobenzen for profylakse og behandling av følgene av akutt og kronisk cerebral redusert gjennomblødning samt neurodegenerative sykdommer

Country Status (26)

Country Link
US (2) US5852053A (no)
EP (1) EP0857065B1 (no)
JP (2) JP4567101B2 (no)
KR (1) KR100423823B1 (no)
AR (1) AR004108A1 (no)
AT (1) ATE178487T1 (no)
AU (1) AU706735B2 (no)
BR (1) BR9610899A (no)
CA (1) CA2188841C (no)
CZ (1) CZ291456B6 (no)
DE (2) DE19539861A1 (no)
DK (1) DK0857065T3 (no)
ES (1) ES2131973T3 (no)
GR (1) GR3030336T3 (no)
HU (1) HU228014B1 (no)
ID (1) ID16489A (no)
IL (1) IL123523A (no)
NO (1) NO316493B1 (no)
NZ (1) NZ326754A (no)
PL (1) PL185714B1 (no)
RU (1) RU2201227C2 (no)
SK (1) SK283222B6 (no)
TW (1) TW457084B (no)
UA (1) UA51681C2 (no)
WO (1) WO1997015300A2 (no)
ZA (1) ZA968991B (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6472165B1 (en) * 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
US6117900A (en) * 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
TWI287984B (en) 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
AR033095A1 (es) * 2001-04-04 2003-12-03 Wyeth Corp Metodos para el tratamiento de motilidad gastrica hiperactiva
US7205307B2 (en) * 2002-02-14 2007-04-17 Icagen, Inc. Pyrimidines as novel openers of potassium ion channels
KR20050089862A (ko) * 2002-12-27 2005-09-08 하. 룬트벡 아크티에 셀스카브 중추신경계 장애의 치료에 유용한 1,2,4-트리아미노벤젠유도체
MXPA05006463A (es) * 2002-12-27 2005-08-26 Lundbeck & Co As H Derivados de 1,2,4-triaminobenceno, utiles para tratar transtornos del sistema nervioso central.
EP1631546A1 (en) * 2003-04-25 2006-03-08 H. Lundbeck A/S Sustituted indoline and indole derivatives
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI357901B (en) 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
EP1861394A1 (en) 2005-03-03 2007-12-05 H.Lundbeck A/S Substituted pyridine derivatives
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
BRPI0716715B1 (pt) * 2006-08-23 2021-07-06 Xenon Pharmaceuticals, Inc Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potássio, seus usos, produto, composição, comprimido e cápsula
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
CA2670966A1 (en) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US20100120906A1 (en) * 2008-07-18 2010-05-13 Valeant Pharmaceuticals International Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
WO2013011518A1 (en) 2011-07-21 2013-01-24 Arch Pharmalabs Limited Process for the preparation of retigabine of the formula i and pharmaceutically acceptable salts thereof
CN103073455B (zh) * 2011-10-25 2015-08-19 中国科学院上海药物研究所 一类新型的kcnq钾通道激动剂、其制备方法和用途
CA2881464C (en) 2012-08-07 2021-12-21 Children's Medical Center Corporation Potassium channel openers for treating neurodegenerative diseases
CN105017085B (zh) 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
WO2021092439A1 (en) 2019-11-08 2021-05-14 Xenon Pharmaceuticals Inc. Methods of treating depressive disorders
IL304920A (en) 2021-02-09 2023-10-01 Xenon Pharmaceuticals Inc A voltage-gated potassium channel opener for use in the treatment of anhedonia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2817334B2 (ja) * 1990-03-29 1998-10-30 株式会社ツムラ 神経細胞保護剤
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
TW280819B (no) * 1993-11-17 1996-07-11 Sumitomo Pharma
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen

Also Published As

Publication number Publication date
HU228014B1 (en) 2012-08-28
US5852053A (en) 1998-12-22
IL123523A0 (en) 1998-10-30
EP0857065A2 (de) 1998-08-12
BR9610899A (pt) 1999-07-13
RU2201227C2 (ru) 2003-03-27
JP4567101B2 (ja) 2010-10-20
UA51681C2 (uk) 2002-12-16
TW457084B (en) 2001-10-01
AU1540097A (en) 1997-05-15
KR100423823B1 (ko) 2004-08-25
AR004108A1 (es) 1998-09-30
KR19990067021A (ko) 1999-08-16
SK52098A3 (en) 1998-09-09
DE19539861A1 (de) 1997-04-30
CZ122598A3 (cs) 1998-09-16
EP0857065B1 (de) 1999-04-07
SK283222B6 (sk) 2003-03-04
ES2131973T3 (es) 1999-08-01
IL123523A (en) 2001-12-23
PL325956A1 (en) 1998-08-17
NO316493B1 (no) 2004-02-02
US5849789A (en) 1998-12-15
DE59601624D1 (de) 1999-05-12
AU706735B2 (en) 1999-06-24
WO1997015300A3 (de) 1997-07-03
DK0857065T3 (da) 1999-10-18
CA2188841C (en) 2006-05-23
CA2188841A1 (en) 1997-04-27
NZ326754A (en) 2000-03-27
WO1997015300A2 (de) 1997-05-01
JP2009007366A (ja) 2009-01-15
HUP9900508A2 (hu) 1999-06-28
HUP9900508A3 (en) 1999-11-29
GR3030336T3 (en) 1999-09-30
ATE178487T1 (de) 1999-04-15
MX9803172A (es) 1998-09-30
JPH11515007A (ja) 1999-12-21
NO981503D0 (no) 1998-04-02
ID16489A (id) 1997-10-02
PL185714B1 (pl) 2003-07-31
CZ291456B6 (cs) 2003-03-12
ZA968991B (en) 1997-06-10

Similar Documents

Publication Publication Date Title
NO981503L (no) Anvendelsen av 2-amino-4-(4-fluorbenzylamino)-1-etoksy-karbonylaminobenzen for profylakse og behandling av f÷lgene av akutt og kronisk cerebral redusert gjennombl÷dning samt neurodegenerative sykdommer
FI962249A7 (fi) Substituoituja pyratsolyylibentseenisulfonamideja tulehduksen hoitoa varten
DE69435243D1 (de) Verwendung vom neurotoxischem Komponent von Botulinum Toxin zur Behandlung von Glattmuskelkrankheiten
PT1083889E (pt) Compostos de tetra-hidronaftaleno e sua utilizacao no tratamento de doencas neurodegenerativas
PT966436E (pt) Arilsulfonamidas e analogos e sua aplicacao para o tratamento de doencas neurodegenerativas
NO972972D0 (no) Sammensetninger for behandling av dermatologiske forstyrrelser og metoder for deres anvendelse
FI973292A7 (fi) Substituoituja isoksatsoleja tulehduksen hoitamiseksi
BR9508886A (pt) Compostos e métodos para o tratamento de câncer
NO20014674D0 (no) Fremgangsmåte for behandling av neurologiske og neuropsykiatriske forstyrrelser
AU7042796A (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
NO961226D0 (no) Blandinger for forebyggelse og behandling av viralinduserte tumorer
BR9606766A (pt) Utilização de compostos e processo para o tratamento e profilaxia de disturbios degenerativos cerebrais
IS4569A (is) Bensamíð til að meðhöndla taugahrörnunarsjúkdóma
BR9606925A (pt) Utilização de compostos e processo para o tratamento e profilaxia da obesidade
ZA958558B (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
BR9608595A (pt) Utilização de n-cicloexil benzamidas para o tratamento de aglições intestinais
FI944687A7 (fi) Koostumus likinäköisyyden ennaltaehkäisemiseksi ja hoitamiseksi
FI953747A0 (fi) Steroideja vaihdevuosivaivojen hoitoon
KR940018945U (ko) 치질치료 및 예방용 좌욕조
EP0596937A4 (en) PLASMALOPSYCHOSINE AND PLASMALOCEREBROSIDE AND METHOD FOR TREATING NEURONAL DISEASES WITH THESE SUBSTANCES.
KR970019262U (ko) 사용경과시간을 알리는 컴퓨터
KR970020846U (ko) 근골격계질환 치료보조용 반창고
KR950032386U (ko) 약재를 내장한 샤워콕
AU3613995A (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
KR940021123U (ko) 두 편광자의 교차를 이용한 작업용 보안경

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees